Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2017, Article ID 2450401, 8 pages
https://doi.org/10.1155/2017/2450401
Research Article

The Clinical Significance of Increased Serum Proinflammatory Cytokines, C-Reactive Protein, and Erythrocyte Sedimentation Rate in Patients with Hidradenitis Suppurativa

1Unidad de Gestión Clínica de Dermatología, Hospital Universitario Puerta del Mar, Cádiz, Spain
2Unidad de Gestión Clínica de Hematología e Inmunología, Hospital Universitario Puerta del Mar, Cádiz, Spain

Correspondence should be addressed to D. Jiménez-Gallo; moc.liamg@ollagzenemijdivad

Received 11 January 2017; Revised 22 May 2017; Accepted 13 June 2017; Published 10 July 2017

Academic Editor: Hermann Gram

Copyright © 2017 D. Jiménez-Gallo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. Prens and I. Deckers, “Pathophysiology of hidradenitis suppurativa: an update,” Journal of the American Academy of Dermatology, vol. 73, pp. S8–S11, 2015. View at Google Scholar
  2. G. B. Jemec, “Clinical practice. Hidradenitis suppurativa,” The New England Journal of Medicine, vol. 366, pp. 158–164, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. H. H. van der Zee, J. D. Laman, J. Boer, and E. P. Prens, “Hidradenitis suppurativa: viewpoint on clinical phenotyping, pathogenesis and novel treatments,” Experimental Dermatology, vol. 21, pp. 735–739, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. D. A. Gold, V. J. Reeder, M. G. Mahan, and I. H. Hamzavi, “The prevalence of metabolic syndrome in patients with hidradenitis suppurativa,” Journal of the American Academy of Dermatology, vol. 70, pp. 699–703, 2014. View at Google Scholar
  5. A. M. Schrader, I. E. Deckers, H. H. van der Zee, J. Boer, and E. P. Prens, “Hidradenitis suppurativa: a retrospective study of 846 Dutch patients to identify factors associated with disease severity,” Journal of the American Academy of Dermatology, vol. 71, pp. 460–467, 2014. View at Google Scholar
  6. G. Kelly and E. P. Prens, “Inflammatory mechanisms in hidradenitis suppurativa,” Dermatologic Clinics, vol. 34, pp. 51–58, 2016. View at Publisher · View at Google Scholar · View at Scopus
  7. H. H. Van der Zee, L. de Ruiter, D. G. van den Broecke, W. A. Dik, J. D. Laman, and E. P. Prens, “Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β,” The British Journal of Dermatology, vol. 164, pp. 1292–1298, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. P. T. Riis, K. Søeby, D. M. Saunte, and G. B. Jemec, “Patients with hidradenitis suppurativa carry a higher systemic inflammatory load than other dermatological patients,” Archives of Dermatological Research, vol. 307, pp. 885–889, 2015. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Martorell, F. J. García-Martínez, D. Jiménez-Gallo et al., “An update on hidradenitis suppurativa (part I): epidemiology, clinical aspects, and definition of disease severity,” Actas Dermo-Sifiliográficas, vol. 106, pp. 703–715, 2015. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Martorell, F. J. García, D. Jiménez-Gallo et al., “Update on hidradenitis suppurative (part II): treatment,” Actas Dermo-Sifiliográficas, vol. 106, pp. 716–724, 2015. View at Publisher · View at Google Scholar · View at Scopus
  11. A. L. Lima, I. Karl, T. Giner et al., “Keratinocytes and neutrophils are important sources of proinflammatory molecules in hidradenitis suppurativa,” The British Journal of Dermatology, vol. 174, pp. 514–521, 2016. View at Publisher · View at Google Scholar · View at Scopus
  12. C. W. Lynde, Y. Poulin, R. Vender, M. Bourcier, and S. Khalil, “Interleukin 17A: toward a new understanding of psoriasis pathogenesis,” Journal of the American Academy of Dermatology, vol. 71, pp. 141–150, 2014. View at Google Scholar
  13. K. A. Cho, J. W. Suh, K. H. Lee, J. L. Kang, and S. Y. Woo, “IL-17 and IL-22 enhance skin inflammation by stimulating the secretion of IL-1β by keratinocytes via the ROS-NLRP3-caspase-1 pathway,” International Immunology, vol. 24, pp. 147–158, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. C. Schlapbach, T. Hänni, N. Yawalkar, and R. E. Hunger, “Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa,” Journal of the American Academy of Dermatology, vol. 65, pp. 790–798, 2011. View at Google Scholar
  15. E. J. Giamarellos-Bourboulis, A. Antonopoulou, C. Petropoulou et al., “Altered innate and adaptive immune responses in patients with hidradenitis suppurativa,” The British Journal of Dermatology, vol. 156, pp. 51–56, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. G. Kelly, C. M. Sweeney, A. M. Tobin, and B. Kirby, “Hidradenitis suppurativa: the role of immune dysregulation,” International Journal of Dermatology, vol. 53, pp. 1186–1196, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Hessam, M. Sand, T. Gambichler, and F. G. Bechara, “Correlation of inflammatory serum markers with disease severity in patients with hidradenitis suppurativa (HS),” Journal of the American Academy of Dermatology, vol. 73, pp. 998–1005, 2015. View at Google Scholar
  18. J. C. Pascual, I. González, D. Corona et al., “Assessment of subclinical atherosclerosis in hidradenitis suppurativa,” Journal of the European Academy of Dermatology and Venereology, vol. 2, 2016. View at Google Scholar
  19. S. E. Bedell and B. T. Bush, “Erythrocyte sedimentation rate. From folklore to facts,” The American Journal of Medicine, vol. 78, p. 1001, 1985. View at Publisher · View at Google Scholar · View at Scopus
  20. Ł. Matusiak, J. Salomon, D. Nowicka-Suszko, A. Bieniek, and J. C. Szepietowski, “Chitinase-3-like protein 1 (YKL-40): novel biomarker of hidradenitis suppurativa disease activity?” Acta Dermato-Venereologica, vol. 95, pp. 736-737, 2015. View at Publisher · View at Google Scholar · View at Scopus
  21. Ł. Matusiak, J. Szczęch, A. Bieniek, D. Nowicka-Suszko, and J. C. Szepietowski, “Increased interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: implications for treatment with anti-IL-17 agents,” Journal of the American Academy of Dermatology, vol. 76, pp. 670–675, 2017. View at Google Scholar
  22. B. I. Gavrilă, C. Ciofu, and V. Stoica, “Biomarkers in rheumatoid arthritis, what is new?” Journal of Medicine and Life, vol. 9, pp. 144–148, 2016. View at Google Scholar
  23. Z. Rezaieyazdi, M. Sahebari, M. R. Hatef et al., “Is there any correlation between high sensitive CRP and disease activity in systemic lupus erythematosus?” Lupus, vol. 20, pp. 1494–1500, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. J. Revuz, “Hidradenitis suppurativa,” Journal of the European Academy of Dermatology and Venereology, vol. 23, pp. 985–998, 2009. View at Google Scholar
  25. J. Revuz, “Évaluation clinique de la sévérité de l’hidradénite suppurée – maladie de Verneuil,” Annales de Dermatologie et de Vénéréologie, vol. 142, pp. 729–735, 2015. View at Google Scholar
  26. H. H. van der Zee and G. B. Jemec, “New insights into the diagnosis of hidradenitis suppurativa: clinical presentations and phenotypes,” Journal of the American Academy of Dermatology, vol. 73, pp. S23–S26, 2015. View at Publisher · View at Google Scholar · View at Scopus
  27. A. B. Kimball, F. Kerdel, D. Adams et al., “Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: a parallel randomized trial,” Annals of Internal Medicine, vol. 157, pp. 846–855, 2012. View at Publisher · View at Google Scholar
  28. F. Porteu and C. Nathan, “Shedding of tumor necrosis factor receptors by activated human neutrophils,” The Journal of Experimental Medicine, vol. 172, pp. 599–607, 1990. View at Publisher · View at Google Scholar · View at Scopus
  29. J. Cohen, Statistical Power Analysis for the Behavioral Sciences, Lawrence Erlbaum Associates, Hilsdale, New Jersey, USA, 2nd edition, 1988.
  30. J. L. Blok, K. Li, C. Brodmerkel, P. Horvátovich, M. F. Jonkman, and B. Horváth, “Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum,” The British Journal of Dermatology, vol. 174, pp. 839–846, 2016. View at Publisher · View at Google Scholar · View at Scopus
  31. L. Matusiak, A. Bieniek, and J. C. Szepietowski, “Increased serum tumour necrosis factor-alpha in hidradenitis suppurativa patients: is there a basis for treatment with anti-tumour necrosis factor-alpha agents?” Acta Dermato-Venereologica, vol. 89, pp. 601–603, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. Ł. Matusiak, A. Bieniek, and J. C. Szepietowski, “Soluble interleukin-2 receptor serum level is a useful marker of hidradenitis suppurativa clinical staging,” Biomarkers, vol. 14, pp. 432–437, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. E. S. Kim, K. P. Garnock-Jones, and S. J. Keam, “Adalimumab: a review in hidradenitis suppurativa,” American Journal of Clinical Dermatology, vol. 17, pp. 545–552, 2016. View at Publisher · View at Google Scholar · View at Scopus
  34. R. A. Lee and D. B. Eisen, “Treatment of hidradenitis suppurativa with biologic medications,” Journal of the American Academy of Dermatology, vol. 73, pp. S82–S88, 2015. View at Google Scholar
  35. G. Kelly, R. Hughes, T. McGarry et al., “Dysregulated cytokine expression in lesional and nonlesional skin in hidradenitis suppurativa,” The British Journal of Dermatology, vol. 173, pp. 1431–1439, 2015. View at Publisher · View at Google Scholar · View at Scopus
  36. D. Schmidt-Arras and S. Rose-John, “IL-6 pathway in the liver: from physiopathology to therapy,” Journal of Hepatology, vol. 64, pp. 1403–1415, 2016. View at Publisher · View at Google Scholar · View at Scopus